NO20034496L - Dihydro-benzo[b][1,4]diazepin-2-on-derivater som MGLUR2- antagonister I - Google Patents

Dihydro-benzo[b][1,4]diazepin-2-on-derivater som MGLUR2- antagonister I

Info

Publication number
NO20034496L
NO20034496L NO20034496A NO20034496A NO20034496L NO 20034496 L NO20034496 L NO 20034496L NO 20034496 A NO20034496 A NO 20034496A NO 20034496 A NO20034496 A NO 20034496A NO 20034496 L NO20034496 L NO 20034496L
Authority
NO
Norway
Prior art keywords
diazepin
benzo
dihydro
derivatives
mglur2 antagonists
Prior art date
Application number
NO20034496A
Other languages
English (en)
Other versions
NO325300B1 (no
NO20034496D0 (no
Inventor
Vincent Mutel
Juergen Wichmann
Geo Adam
Erwin Goetchi
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20034496L publication Critical patent/NO20034496L/no
Publication of NO20034496D0 publication Critical patent/NO20034496D0/no
Publication of NO325300B1 publication Critical patent/NO325300B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20034496A 2001-04-12 2003-10-08 Dihydro-benzo[b][1,4]diazepin-2-on-derivater, fremgangsmate for fremstilling av slike forbindelser, medikament inneholdende slike forbindelser, slike forbindelser for behandling eller forebygging av sykdommer samt anvendelse av disse forbindelsene for fremstilling av medikamenter for behandling eller forebygging av sykdommer. NO325300B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109126 2001-04-12
PCT/EP2002/003643 WO2002083665A1 (en) 2001-04-12 2002-04-02 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I

Publications (3)

Publication Number Publication Date
NO20034496L true NO20034496L (no) 2003-10-08
NO20034496D0 NO20034496D0 (no) 2003-10-08
NO325300B1 NO325300B1 (no) 2008-03-25

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034496A NO325300B1 (no) 2001-04-12 2003-10-08 Dihydro-benzo[b][1,4]diazepin-2-on-derivater, fremgangsmate for fremstilling av slike forbindelser, medikament inneholdende slike forbindelser, slike forbindelser for behandling eller forebygging av sykdommer samt anvendelse av disse forbindelsene for fremstilling av medikamenter for behandling eller forebygging av sykdommer.

Country Status (37)

Country Link
US (1) US6548495B2 (no)
EP (1) EP1379522B1 (no)
JP (1) JP4043953B2 (no)
KR (1) KR100566178B1 (no)
CN (1) CN1268626C (no)
AR (1) AR035456A1 (no)
AT (1) ATE287883T1 (no)
AU (1) AU2002310912B2 (no)
BG (1) BG108253A (no)
BR (1) BR0208887A (no)
CA (1) CA2441771C (no)
CZ (1) CZ20033002A3 (no)
DE (1) DE60202761T2 (no)
DK (1) DK1379522T3 (no)
EC (1) ECSP034796A (no)
ES (1) ES2235044T3 (no)
GT (1) GT200200072A (no)
HR (1) HRP20030791B1 (no)
HU (1) HUP0400991A3 (no)
IL (2) IL158021A0 (no)
JO (1) JO2273B1 (no)
MA (1) MA27011A1 (no)
MX (1) MXPA03009317A (no)
MY (1) MY130369A (no)
NO (1) NO325300B1 (no)
NZ (1) NZ528345A (no)
PA (1) PA8543201A1 (no)
PE (1) PE20021072A1 (no)
PL (1) PL367086A1 (no)
PT (1) PT1379522E (no)
RU (1) RU2270197C2 (no)
SI (1) SI1379522T1 (no)
SK (1) SK13692003A3 (no)
UY (1) UY27259A1 (no)
WO (1) WO2002083665A1 (no)
YU (1) YU79103A (no)
ZA (1) ZA200307242B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003740A (es) * 1999-10-15 2002-09-30 Hoffmann La Roche Derivados de benzodiazepina.
KR100764330B1 (ko) * 2003-07-25 2007-10-05 에프. 호프만-라 로슈 아게 급성 및/또는 만성 신경학적 장애의 치료를 위한ｍＧｌｕＲ2 길항제 및 ＡＣｈＥ 억제제의 조합물
CA2586931C (en) 2004-11-05 2013-08-06 Paul Spurr Process for preparation of isonicotinic acid derivatives
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
JP2010524879A (ja) * 2007-04-19 2010-07-22 エフ．ホフマン−ラ ロシュ アーゲー ジヒドロ−ベンゾ［ｂ］［１，４］ジアゼピン−２−オンスルホンアミド誘導体
CA2696948C (en) 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
KR20100080597A (ko) * 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된-４-페닐-1ｈ-피리딘-2-온
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
BRPI0921333A2 (pt) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
KR20150070187A (ko) 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 ｍｇｌｕ２／３ 길항제
PL2963043T3 (pl) * 2013-02-28 2018-10-31 Eisai R&D Management Co., Ltd. Pochodna tetrahydroimidazo[1,5-d][1,4]oksazepiny
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
EP3134089A2 (en) 2014-04-23 2017-03-01 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of intellectual disabilities
JP6552061B2 (ja) * 2014-06-10 2019-07-31 サンフォード−バーンハム メディカル リサーチ インスティテュート 代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU953819A1 (ru) * 1980-08-25 1991-09-23 Физико-химический институт АН УССР 1-(Гидразинокарбонил)алкил-1,2-дигидро-3Н-1,4-бенздиазепин-2-оны, обладающие транквилизирующими и противосудорожными свойствами
EP1210338A2 (en) * 1999-08-05 2002-06-05 IGT Pharma Inc. 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
TR200201023T2 (tr) * 1999-10-15 2002-09-23 F. Hoffmann-La Roche Ag Benzodiazepin türevleri.
MXPA02003740A (es) * 1999-10-15 2002-09-30 Hoffmann La Roche Derivados de benzodiazepina.

Also Published As

Publication number Publication date
US6548495B2 (en) 2003-04-15
YU79103A (sh) 2006-05-25
KR100566178B1 (ko) 2006-03-29
HUP0400991A3 (en) 2009-06-29
EP1379522B1 (en) 2005-01-26
CN1268626C (zh) 2006-08-09
CA2441771A1 (en) 2002-10-24
BG108253A (bg) 2005-03-31
GT200200072A (es) 2003-06-19
HK1068339A1 (en) 2005-04-29
IL158021A (en) 2010-04-15
ES2235044T3 (es) 2005-07-01
JO2273B1 (en) 2005-04-07
MA27011A1 (fr) 2004-12-20
BR0208887A (pt) 2004-06-29
SK13692003A3 (sk) 2004-05-04
HUP0400991A2 (hu) 2004-08-30
CN1522252A (zh) 2004-08-18
ATE287883T1 (de) 2005-02-15
PT1379522E (pt) 2005-05-31
SI1379522T1 (en) 2005-04-30
US20020198197A1 (en) 2002-12-26
HRP20030791B1 (en) 2006-06-30
PE20021072A1 (es) 2002-12-07
ZA200307242B (en) 2004-12-16
EP1379522A1 (en) 2004-01-14
ECSP034796A (es) 2003-12-01
DE60202761D1 (de) 2005-03-03
AU2002310912B2 (en) 2005-06-16
PA8543201A1 (es) 2002-10-31
JP4043953B2 (ja) 2008-02-06
DE60202761T2 (de) 2006-01-12
JP2004525965A (ja) 2004-08-26
DK1379522T3 (da) 2005-05-30
NO325300B1 (no) 2008-03-25
CA2441771C (en) 2008-12-30
PL367086A1 (en) 2005-02-21
MXPA03009317A (es) 2004-02-12
AR035456A1 (es) 2004-05-26
NZ528345A (en) 2005-04-29
RU2270197C2 (ru) 2006-02-20
UY27259A1 (es) 2002-10-31
NO20034496D0 (no) 2003-10-08
WO2002083665A1 (en) 2002-10-24
KR20030088502A (ko) 2003-11-19
IL158021A0 (en) 2004-03-28
MY130369A (en) 2007-06-29
RU2003130648A (ru) 2005-04-10
HRP20030791A2 (en) 2005-06-30
CZ20033002A3 (cs) 2004-03-17

Similar Documents

Publication Publication Date Title
DK1379511T3 (da) Dihydro-benzo[b][1,4]diazepin-2-on-derivater som mGLuR2-antagonister II
NO20034496D0 (no) Dihydro-benzo[b][1,4]diazepin-2-on-derivater som MGLUR2- antagonister I
NO20043022L (no) 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
FR14C0066I2 (fr) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles
NO20014412D0 (no) Forbindelser nyttige som anti-inflammatoriske midler
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
NO20011738D0 (no) Heterocyclylaminometyloksazolidinoner som antibakterielle midler
NO20032142L (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
ATE326467T1 (de) Imidazo 1,2-aöpyridine
PT1210349E (pt) Pirazolo-¬4,3-d|-pirimidinas
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
NO20015668D0 (no) Substituerte imidazotiazoler som antidepressive midler
DK1181288T3 (da) Bicycliske oxazolidinoner som antibakterielle midler
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
DK0964863T3 (da) Oxazolidinoner som 5-HT2A-antagonister
DK1261588T3 (da) Imidazolforbindelser som alfa2-adrenoceptorantagonister
NO20002575D0 (no) Substituerte oksimer som neurokininantagonister
PT1326866E (pt) 3,4-di-hidropirido[1,2-a]pirimidinas substituidas
NO20011309L (no) Benzotieno [3,2-c]pyridiner som<alfa>2-antagonister
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
NO20021249L (no) Tienoisoksazolfenoksyusubstituerte etyl- og propylderivater anvendbare som D4antagonister
ES1047631Y (es) Dispositivo para la fabricacion de piezas modulares para la construccion.
SE9902902D0 (sv) New formulation
ITRM20000199A0 (it) Formulazione.
SE0100199D0 (sv) New formulation